We also analyzed the relationship between PD-1 expression and risk stratification in AML patients, which indicated that there were no significant differences in PD-1 expression on CD4+ and CD8+ T lymphocytes among low-risk, intermediate-risk, and high-risk groups (Fig. 5I and J). This evidence concerns the gene CD4 and acute myeloid leukemia.